Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cabazitaxel vs docetaxel in chemotherapy-naïve metastatic castration-resistant prostate cancer
CTR20131729Phase 3Completed
- Sponsor
- Sanofi
- Start
- Mar 2016
- Modality
- Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of cabazitaxel in metastatic castration-resistant prostate cancer (mCRPC), sponsored by Sanofi. Started Mar 2016; status: completed.
02
Drugs
cabazitaxel
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on CTR20131729.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20131729.